Your shopping cart is currently empty

CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,870 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $2,440 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $4,090 | 10-14 weeks | 10-14 weeks |
| Description | CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM. |
| Targets&IC50 | CXCR7:13 nM (ki) |
| In vitro | CXCR7 modulator 2 showed strong CXCR7 binding affinity (Ki = 13 nM) and β-arrestin activity (EC50 = 11 nM). Compared with 11c, CXCR7 modulator 2 also showed improved selectivity in the GPCR panel and showed a higher therapeutic index in the hERG patch clamp assay. CXCR7 modulator 2 exhibited medium to high in vitro turnover in NADPH- supplemented mouse liver microsomes (MLM, 93 μL / min / mg) and hepatocytes (28 μL / min per million cells), which was shown to be more comparable in MDCK Poor passive absorption permeability type II permeability measurement method, and has good water solubility. CXCR7 regulator 2 is rapidly absorbed, with an average maximum plasma concentration (Cmax) of 682 ng / mL, which appears at 0.25 h (Tmax). The corresponding average area under the plasma concentration-time curve (AUC) is 740 ng / mL / h. |
| In vivo | The administration of isoproterenol for 9 days induces cardiac fibrosis, evidenced by a fourfold increase in collagen deposition detected by Pixirius red staining relative to the control group. Treatment with CXCR7 modulator 2 significantly reduces cardiac fibrosis, demonstrating its protective effect on CXCR7 modulation in isoproterenol-induced cardiac injury. |
| Molecular Weight | 522.68 |
| Formula | C29H42N6O3 |
| Cas No. | 2227426-37-9 |
| Smiles | CCc1ccn2ccnc2c1N1CCCN(CC1)[C@@H](CC(N)=O)C1CCN(CC1)C(=O)[C@H]1C[C@@H]2CC[C@H]1O2 |
| Relative Density. | 1.40 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (478.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.31 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.